NCT04525079View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 18, 2020

Primary Completion Date

August 7, 2020

Study Completion Date

November 5, 2020

Conditions
SARS-CoV-2 Infection
Interventions
DRUG

CT-P59

CT-P59 will be administered

DRUG

Placebo

Placebo-matching CT-P59

Trial Locations (1)

Unknown

Chungnam National University Hospital, Daejeon

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04525079 - To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects | Biotech Hunter | Biotech Hunter